Department of Neurosurgery, Xiangya Hospital of Central South University, Changsha, 410008, Hunan, People's Republic of China.
Department of Thoracic Surgery, Xiangya Hospital of Central South University, Changsha, 410008, Hunan, People's Republic of China.
Cancer Lett. 2020 Apr 28;476:1-12. doi: 10.1016/j.canlet.2020.02.002. Epub 2020 Feb 7.
Gliomas are intrinsic brain tumors that originate from neuroglial progenitor cells. Conventional therapies, including surgery, chemotherapy, and radiotherapy, have achieved limited improvements in the prognosis of glioma patients. Immunotherapy, a revolution in cancer treatment, has become a promising strategy with the ability to penetrate the blood-brain barrier since the pioneering discovery of lymphatics in the central nervous system. Here we detail the current management of gliomas and previous studies assessing different immunotherapies in gliomas, despite the fact that the associated clinical trials have not been completed yet. Moreover, several drugs that have undergone clinical trials are listed as novel strategies for future application; however, these clinical trials have indicated limited efficacy in glioma. Therefore, additional studies are warranted to evaluate novel therapeutic approaches in glioma treatment.
神经胶质瘤是源自神经胶质祖细胞的脑内肿瘤。包括手术、化疗和放疗在内的常规疗法，已使神经胶质瘤患者的预后得到了有限的改善。免疫疗法作为癌症治疗的一场革命，自从中枢神经系统淋巴管被发现以来，由于其能够穿透血脑屏障，已成为一种很有前途的策略。在此，我们详细介绍了目前对神经胶质瘤的治疗方法，以及以前对神经胶质瘤不同免疫疗法的评估，尽管相关的临床试验尚未完成。此外，还列出了几种已进行临床试验的药物，作为未来应用的新策略；然而，这些临床试验表明这些药物在神经胶质瘤中的疗效有限。因此，需要进一步的研究来评估神经胶质瘤治疗的新的治疗方法。
